Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Jenburkt Pharmaceuticals Ltd Stock Analysis

Small Cap
Evaluated by 664 users | BSE: 524731 | NSE: |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 39.87%33.24%27.79%28.94%28.46%25.46%25.8%28.18%27.45%17.79%17.97%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 56.959.869.376.285.293.6103115123119109124
Y-o-Y Gr. Rt.-5.1%15.9%9.9%11.8%9.8%10.4%11%7%-3.1%-8.1%-
Adjusted EPS (Rs.) 12.8712.5813.0515.7220.7122.8928.9136.9343.231.8435.6148.91
Y-o-Y Gr. Rt.--2.3%3.7%20.5%31.7%10.5%26.3%27.7%17%-26.3%11.8%-
Book Value per Share (Rs.) 31.3140.2348.7258.7371.9286.44117.09133.48168.79174.32214.55233.95
Adjusted Net Profit 65.96.17.39.610.613.41719.814.616.322
Net Op. Cash Flow (Rs. Cr.) 7.36.94.511.48.77.81016.2131519.5-
Debt to Cash Flow from Ops 0.30.341.020.180.760.690.640.010.580.230.19-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Jenburkt Pharmaceuticals Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 6.9%3.2%-1.6%-8.1%
Adjusted EPS 12.3%9.2%-1.2%11.8%
Book Value per Share 20.419.917.123.1
Share Price 21.8% -0.4% -4.9% 32.4%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 48.0735.1529.3329.2631.728.9128.4129.328.5918.5618.3121.81
Operating Profit Margin (%) 17.9115.8314.5815.1117.917.5919.1220.7420.3616.6118.1522.31
Net Profit Margin (%) 10.519.778.759.5911.311.3713.0114.7816.1712.2914.9518.09
Debt to Equity 0.150.130.20.070.20.130.1200.10.040.040
Working Capital Days 104111107867371656984101129187
Cash Conversion Cycle 2135443834383739567164137
Loading price chart...
Entity Percentage Holding
Promoters 45.73%
Institutions 4.37%
Non-Institutions 49.90%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Jenburkt Pharmaceuticals Ltd's earnings have grown by 9.2%, whereas share price has declined -0.4% CAGR over the past five years, indicating the company’s share price is likely undervalued. However, for specific investment actions please consult your investment advisor.

Jenburkt Pharmaceuticals Ltd share price has appreciated 21.8% annually (CAGR) over the past ten years.

Data is not available for this company.

Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta

Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt's

Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta

Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt's headquarters are ocated in Mumbai, from where it’s entire operations

The company has a state-of-the-art manufacturing plants at Sihor-Gujarat,in India. The plant is modern and well equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products.

The plant is approved as per WHO guidelines for compliances with current GMPrequirements, apart from approvals from various countries.

Jenburkt, has 25 superstockists located in different corners of India, it has approximately 1000 stockists, who buy from Superstockist and sell to chemists. Jenburkt also caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.

Product range of the company includes: 

Consumer Division:

  • Nocal Tablets
  • Nocal Sachet   
  • Nocal Granular 

Pharmaceutical Division: 

  • Anti-Arthritic
  • Antibiotics 
  • Anti-Diabetic 
  • Nutraceuticals 
  • Anti-Inflammory Analgesics 
  • Gastro Intenstinal 
  • Dermatologicals
  • Aphrodisiac 
  • Anti-Osteoporotic
  • Anti-Cough, Cold & Allergy
  • Anti-Ulcerants

Awards

2010 - The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi.
2011 - The Company was bestowed with "National Award for Excellence in Cost Management-2010" as the "FIRST"awardee under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI).
The Company has been awarded an NSIC-CRISIL rating of "NSIC-CRISIL SE-1A" on June 30, 2011. The rating indicates ""Highest performance capability and High financial strength".

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback